Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THR 317 (Primary) ; Etoposide; Temozolomide
Indications Alveolar soft part sarcoma; Ewing's sarcoma; Medulloblastoma; Neuroblastoma; Rhabdomyosarcoma
Focus Adverse reactions
Sponsors Oncurious

Most Recent Events

14 Jul 2022 Results published in the Clinical Cancer Research
21 May 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
12 Apr 2021 According to an Oncurious media release, results from this trial were presented at the annual meeting of the American Association for Cancer Research (AACR) 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com